PRESS RELEASE

XIFIN Announces Availability of CEO Guide to Molecular Diagnostic Reimbursement and Commercialization

XIFIN, Inc., the leading provider of revenue cycle management for diagnostic service providers, has announced the release of a newly published  white paper, “A CEO’s Guide to Molecular Diagnostic Reimbursement: Navigating the Many Challenges of Reimbursement and Commercialization,” written by industry expert Rina Wolf, VP of Commercialization Strategies, Consulting and Industry Affairs at XIFIN, Inc. Molecular diagnostic testing identifies molecular and genetic markers of an individual patient to determine the benefit of a specific treatment, or risk of developing a specific health condition.

“The goal of this white paper is to promote discussion and educate the market on issues impacting molecular diagnostic testing and reimbursement to help advance personalized medicine,” said Wolf. “The white paper will enable laboratory professionals and executives to access a comprehensive, one-of-a-kind resource to help make informed decisions regarding successful commercialization in the molecular diagnostics market.”

The white paper, hosted by Robert Michel, Editor-In-Chief of The Dark Report and President of The Dark Intelligence Group, Inc., provides executives with a roadmap for guiding their companies to market while navigating the unique hurdles of the molecular diagnostic testing environment.  “Molecular diagnostics is growing at a very fast rate and has the potential to significantly impact disease management and individual patient outcomes,” stated Michel. “This white paper discusses many of the trends and challenges molecular diagnostics testing companies confront when they are ready to commercialize their new assays and enter into a highly competitive market. The information provided will help companies assess their needs and develop appropriate strategies.”

Topics discussed in the white paper include:

  • Go-to-market considerations, including how to establish clinical utility, calculate cost of goods and understand unique billing policies and regulations
  • Reimbursement requirements and options
  • Coverage and contracting factors
  • Billing strategies: outsourcing vs. in-house

XIFIN advocates on behalf of both early stage and leading laboratories and molecular diagnostic companies involved in technologies that advance personalized medicine and is a long standing member of various industry organizations including the Personalized Medicine Coalition (PMC), the American Clinical Laboratories Association (ACLA) and California Clinical Laboratory Association (CCLA).

The white paper is available for free download at the Dark Daily website.  Click here to access, “A CEO’s Guide to Molecular Diagnostic Reimbursement: Navigating the Many Challenges of Reimbursement and Commercialization.

Contacts:

Bill Taylor
Vice President, Marketing
XIFIN, Inc.
858.436.2995
btaylor@xifin.com

Myla Wagner
Myla Wagner Public Relations
925.736.7515
myla@mylawagnerpr.com


About XIFIN

XIFIN is an innovative software and services company dedicated to optimizing the economics of healthcare. The company's cloud-based technology and business intelligence platform links healthcare stakeholders in the delivery and reimbursement of care, optimizing both business and patient outcomes and providing informed, streamlined diagnostic and business decision-making. To learn more, visit www.XIFIN.com, or follow XIFIN on Twitter at www.twitter.com/#!/xifin.


XIFIN

Media Relations

To speak with XIFIN directly, contact Fran DuCharme at 858.436.2939 or complete the form below for assistance.

To speak with our PR firm, contact Myla Wagner at 925.736.7515.